Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Ciara J Molloy, Jennifer Cooke, Nicholas J F Gatford, Alejandro Rivera-Olvera, Sahar Avazzadeh, Judith R Homberg, Joanes Grandjean, Cathy Fernandes, Sanbing Shen, Eva Loth, Deepak P Srivastava, Louise Gallagher
Multiple molecular pathways and cellular processes have been implicated in the neurobiology of autism and other neurodevelopmental conditions. There is a current focus on synaptic gene conditions, or synaptopathies, which refer to clinical conditions associated with rare genetic variants disrupting genes involved in synaptic biology. Synaptopathies are commonly associated with autism and developmental delay and may be associated with a range of other neuropsychiatric outcomes. Altered synaptic biology is suggested by both preclinical and clinical studies in autism based on evidence of differences in early brain structural development and altered glutamatergic and GABAergic neurotransmission potentially perturbing excitatory and inhibitory balance...
2023: Frontiers in Molecular Neuroscience
#2
REVIEW
Ciara J Molloy, Ciara Quigley, Áine McNicholas, Linda Lisanti, Louise Gallagher
The heritability of intelligence or general cognitive ability is estimated at 41% and 66% in children and adults respectively. Many rare copy number variants are associated with neurodevelopmental and neuropsychiatric conditions (ND-CNV), including schizophrenia and autism spectrum disorders, and may contribute to the observed variability in cognitive ability. Here, we reviewed studies of intelligence quotient or cognitive function in ND-CNV carriers, from both general population and clinical cohorts, to understand the cognitive impact of ND-CNV in both contexts and identify potential genotype-specific cognitive phenotypes...
April 8, 2023: Translational Psychiatry
#3
REVIEW
Xianghong Arakaki, Rebecca J Arechavala, Elizabeth H Choy, Jayveeritz Bautista, Bishop Bliss, Cathleen Molloy, Daw-An Wu, Shinsuke Shimojo, Yang Jiang, Michael T Kleinman, Robert A Kloner
The heart and brain have bi-directional influences on each other, including autonomic regulation and hemodynamic connections. Heart rate variability (HRV) measures variation in beat-to-beat intervals. New findings about disorganized sinus rhythm (erratic rhythm, quantified as heart rate fragmentation, HRF) are discussed and suggest overestimation of autonomic activities in HRV changes, especially during aging or cardiovascular events. When excluding HRF, HRV is regulated via the central autonomic network (CAN)...
2023: Frontiers in Neuroscience
#4
JOURNAL ARTICLE
Nathalie Beinhölzl, Eóin N Molloy, Rachel G Zsido, Thalia Richter, Fabian A Piecha, Gergana Zheleva, Ulrike Scharrer, Ralf Regenthal, Arno Villringer, Hadas Okon-Singer, Julia Sacher
Previous findings in healthy humans suggest that selective serotonin reuptake inhibitors (SSRIs) modulate emotional processing via earlier changes in attention. However, many previous studies have provided inconsistent findings. One possible reason for such inconsistencies is that these studies did not control for the influence of either sex or sex hormone fluctuations. To address this inconsistency, we administered 20 mg escitalopram or placebo for seven consecutive days in a randomized, double-blind, placebo-controlled design to sixty healthy female participants with a minimum of 3 months oral contraceptive (OC) intake...
2022: Frontiers in Neuroscience
#5
JOURNAL ARTICLE
Edward Beamer, Mary Isabel O'Dea, Aisling A Garvey, Jonathon Smith, Aida Menéndez-Méndez, Lynne Kelly, Andreea Pavel, Sean Quinlan, Mariana Alves, Eva M Jimenez-Mateos, Faming Tian, Eugene Dempsey, Nicholas Dale, Deirdre M Murray, Geraldine B Boylan, Eleanor J Molloy, Tobias Engel
Background: Evidence suggests that earlier diagnosis and initiation of treatment immediately after birth is critical for improved neurodevelopmental outcomes following neonatal encephalopathy (NE). Current diagnostic tests are, however, mainly restricted to clinical diagnosis with no molecular tests available. Purines including adenosine are released during brain injury such as hypoxia and are also present in biofluids. Whether blood purine changes can be used to diagnose NE has not been investigated to date...
2021: Frontiers in Molecular Neuroscience
#6
JOURNAL ARTICLE
Stephanie Lowenhaupt, Angela Molloy
The COVID-19 pandemic abruptly forced changes in how to conduct multicenter clinical research. Gone were the days of face-to-face meetings and working together in person. Virtual teams became the norm rather than exception. The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT: NN) was created with a vision to conduct studies in neurological diseases through partnership with academia, private foundations and industry. 1 A fundamental aspect of the establishment and maintenance of this network was and is the NeuroNEXT virtual coordinator network...
September 2021: Contemporary Clinical Trials Communications
#7
JOURNAL ARTICLE
Elham Khajehali, Sophie Bradley, Emma T van der Westhuizen, Colin Molloy, Celine Valant, Lisa Finlayson, Craig W Lindsley, Patrick M Sexton, Andrew B Tobin, Arthur Christopoulos
Designer receptors exclusively activated by designer drugs (DREADDs) have been successfully employed to activate signaling pathways associated with specific muscarinic acetylcholine receptor (mAChR) subtypes. The M1 DREADD mAChR displays minimal responsiveness to the endogenous agonist acetylcholine (ACh) but responds to clozapine- N -oxide (CNO), an otherwise pharmacologically inert ligand. We have previously shown that benzyl quinolone carboxylic acid (BQCA), an M1 mAChR positive allosteric modulator (PAM), can rescue ACh responsiveness at these receptors...
November 16, 2020: ACS Chemical Neuroscience
#8
JOURNAL ARTICLE
Merit Cudkowicz, Marianne K Chase, Christopher S Coffey, Dixie J Ecklund, Brenda J Thornell, Codrin Lungu, Katy Mahoney, Laurie Gutmann, Jeremy M Shefner, Kevin J Staley, Michael Bosch, Eric Foster, Jeffrey D Long, Emine O Bayman, James Torner, Jon Yankey, Richard Peters, Trevis Huff, Robin A Conwit, Shlomo Shinnar, Donna Patch, Basil T Darras, Audrey Ellis, Roger J Packer, Karen S Marder, Claudia A Chiriboga, Claire Henchcliffe, Joyce Ann Moran, Blagovest Nikolov, Stewart A Factor, Carole Seeley, Steven M Greenberg, Anthony A Amato, Sara DeGregorio, Tanya Simuni, Tina Ward, John T Kissel, Stephen J Kolb, Amy Bartlett, Joseph F Quinn, Kellie Keith, Steven R Levine, Nadege Gilles, Patricia K Coyle, Jessica Lamb, Gil I Wolfe, Annemarie Crumlish, Luis Mejico, Muhammad Maaz Iqbal, James D Bowen, Caryl Tongco, Louis B Nabors, Khurram Bashir, Melanie Benge, Craig M McDonald, Erik K Henricson, Björn Oskarsson, Bruce H Dobkin, Catherine Canamar, Tracy A Glauser, Daniel Woo, Angela Molloy, Peggy Clark, Timothy L Vollmer, Alexander J Stein, Richard J Barohn, Mazen M Dimachkie, Jean-Baptiste Le Pichon, Michael G Benatar, Julie Steele, Lawrence Wechsler, Paula R Clemens, Christine Amity, Robert G Holloway, Christine Annis, Mark P Goldberg, Mariam Andersen, Susan T Iannaccone, A Gordon Smith, J Robinson Singleton, Mariana Doudova, E Clarke Haley, Mark S Quigg, Stephanie Lowenhaupt, Beth A Malow, Karen Adkins, David B Clifford, Mengesha A Teshome, Noreen Connolly
Importance: One major advantage of developing large, federally funded networks for clinical research in neurology is the ability to have a trial-ready network that can efficiently conduct scientifically rigorous projects to improve the health of people with neurologic disorders. Observations: National Institute of Neurological Disorders and Stroke Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) was established in 2011 and renewed in 2018 with the goal of being an efficient network to test between 5 and 7 promising new agents in phase II clinical trials...
March 23, 2020: JAMA Neurology
#9
JOURNAL ARTICLE
Michael Kruepke, Erin K Molloy, Konrad Bresin, Aron K Barbey, Edelyn Verona
Humans make moral judgments every day, and research demonstrates that these evaluations are based on a host of related event features (e.g., harm, legality). In order to acquire systematic data on how moral judgments are made, our assessments need to be expanded to include real-life, ecologically valid stimuli that take into account the numerous event features that are known to influence moral judgment. To facilitate this, Knutson et al. (in Social Cognitive and Affective Neuroscience, 5(4), 378-384, 2010) developed vignettes based on real-life episodic memories rated concurrently on key moral features; however, the method is time intensive (~1...
June 2018: Behavior Research Methods
#10
JOURNAL ARTICLE
Rasmus M Birn, Erin K Molloy, Rémi Patriat, Taurean Parker, Timothy B Meier, Gregory R Kirk, Veena A Nair, M Elizabeth Meyerand, Vivek Prabhakaran
There has been an increasing use of functional magnetic resonance imaging (fMRI) by the neuroscience community to examine differences in functional connectivity between normal control groups and populations of interest. Understanding the reliability of these functional connections is essential to the study of neurological development and degenerate neuropathological conditions. To date, most research assessing the reliability with which resting-state functional connectivity characterizes the brain's functional networks has been on scans between 3 and 11 min in length...
December 2013: NeuroImage
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
